Related Experiment Video
Updated: Dec 20, 2025
09:44
Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
Published on: January 29, 2019
10.5K
Multicenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt Lymphoma
Mark Roschewski1, Kieron Dunleavy2, Jeremy S Abramson3
1Lymphoid Malignancies Branch, National Cancer Institute, Bethesda, MD.
Summary
Dose-adjusted EPOCH-R chemotherapy offers an effective and well-tolerated treatment for adult Burkitt lymphoma, showing high event-free survival regardless of age or HIV status. Further research is needed for patients with central nervous system involvement.
Area of Science:
- Hematology
- Oncology
- Clinical Trials
Background:
- Burkitt lymphoma is an aggressive B-cell malignancy requiring intensive chemotherapy.
- Current treatment regimens, derived from pediatric leukemia protocols, are associated with significant acute toxicity and late sequelae in adults.
- There is a need for less intensive yet effective therapeutic strategies for adult Burkitt lymphoma.
Purpose of the Study:
- To evaluate the efficacy and safety of dose-adjusted etoposide, doxorubicin, cyclophosphamide, vincristine, prednisone, and rituximab (DA-EPOCH-R) in treating adult Burkitt lymphoma.
- To determine if DA-EPOCH-R can reduce the toxicity associated with highly dose-intensive chemotherapy regimens.
- To assess event-free survival (EFS) and overall survival (OS) in a risk-adapted approach.
Main Methods:
- A multicenter, risk-adapted study was conducted involving untreated adult Burkitt lymphoma patients.
- Low-risk patients received three cycles of DA-EPOCH-R, while high-risk patients received six cycles with central nervous system (CNS) prophylaxis.
- Primary endpoint was EFS; secondary endpoints included toxicity, EFS predictors, and OS.
Main Results:
- 113 adult patients were enrolled; 87% were high-risk, with a median age of 49 years.
- At a median follow-up of 58.7 months, EFS was 84.5% and OS was 87.0%.
- EFS was 100% for low-risk and 82.1% for high-risk patients; therapy was effective across age, HIV status, and risk groups. CSF involvement was linked to higher risk of toxicity and treatment failure.
Conclusions:
- Risk-adapted DA-EPOCH-R therapy demonstrates effectiveness and good tolerability in adult Burkitt lymphoma patients, irrespective of age or HIV status.
- Central nervous system involvement remains a critical factor associated with adverse outcomes, necessitating improved therapeutic strategies.
- The study highlights DA-EPOCH-R as a viable alternative to highly intensive chemotherapy for adult Burkitt lymphoma.
More Related Videos
10:33Expedited Radiation Biodosimetry by Automated Dicentric Chromosome Identification ADCI and Dose Estimation
Published on: September 4, 2017
16.4K
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
9.1K
Related Concept Videos
01:11Bioavailability Study Design: Single Versus Multiple Dose Studies
129
Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
129
01:25Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant
143
In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
143
01:28Dosage Regimens: Designs and Approaches
184
Designing a dosage regimen, which refers to the manner of drug administration, is a complex process involving the selection of drug dose, route, and frequency. This process is underpinned by pharmacokinetic parameters derived from tests and population averages. These parameters are then tailored to patient-specific variables such as diagnosis, demographics, and allergy status. Once therapy commences, therapeutic response monitoring is critical and achieved through clinical and physical...
184
01:28Pulmonary Tuberculosis V
465
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
465
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
147
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
147
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
323
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
323